NanoViricides Inc
$ 1.22
9.91%
04 Dec - close price
- Market Cap 21,956,300 USD
- Current Price $ 1.22
- High / Low $ 1.25 / 1.10
- Stock P/E N/A
- Book Value 0.41
- EPS -0.50
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -0.94 %
- 52 Week High 2.23
- 52 Week Low 0.94
About
NanoViricides Inc. (NNVC) is an innovative nanobiopharmaceutical firm headquartered in Shelton, Connecticut, dedicated to the research and development of cutting-edge antiviral therapies. Leveraging its proprietary nanomedicine platform, the company creates targeted treatments that address various viral infections and significant unmet medical needs within the healthcare sector. With a robust clinical and preclinical pipeline, NanoViricides is well-positioned for substantial growth in the evolving landscape of antiviral solutions and continues to make strides in bringing its advanced therapies to market.
Analyst Target Price
$7.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-03 | 2025-09-03 | 2025-05-12 | 2025-02-12 | 2024-11-12 | 2024-08-28 | 2024-05-15 | 2024-02-14 | 2023-10-13 | 2023-08-30 | 2023-05-15 | 2023-02-15 |
| Reported EPS | -0.1 | -0.13 | -0.1383 | -0.1391 | -0.228 | -0.19 | -0.16 | -0.18 | -0.15 | -0.3052 | -0.1463 | -0.15 |
| Estimated EPS | -0.18 | -0.2 | -0.19 | -0.18 | -0.17 | -0.31 | -0.19 | -0.19 | -0.17 | -0.17 | -0.17 | -0.16 |
| Surprise | 0.08 | 0.07 | 0.0517 | 0.0409 | -0.058 | 0.12 | 0.03 | 0.01 | 0.02 | -0.1352 | 0.0237 | 0.01 |
| Surprise Percentage | 44.4444% | 35% | 27.2105% | 22.7222% | -34.1176% | 38.7097% | 15.7895% | 5.2632% | 11.7647% | -79.5294% | 13.9412% | 6.25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NNVC
2025-10-20 00:03:03
NanoViricides discusses the multi-billion-dollar market potential of its broad-spectrum antiviral drug, NV-387, due to its effectiveness against multiple viruses including Influenza, Coronaviruses, RSV, MPox, and Measles. The company plans to pursue Phase II clinical trials for MPox, aiming for the first-ever drug approval for the disease, and will seek orphan drug status for several indications. NV-387 is also positioned as a strategic asset for pandemic preparedness, offering a broad-spectrum, low-cost solution against numerous viral threats by targeting HSPG, which most pathogenic human viruses bind to.
2025-10-16 00:43:56
NanoViricides is pursuing a dual-track clinical strategy for its broad-spectrum antiviral drug candidate, NV-387. The first track involves Phase 2 clinical trials for MPox in Congo, potentially supported by US biodefense funding. The second track focuses on respiratory viral diseases like flu, RSV, and coronaviruses, with an adaptive "basket-type" trial planned in India, potentially leading to focused US trials.
2025-10-15 21:15:23
NanoViricides (NYSE American: NNVC) is pursuing a dual-track clinical strategy for its broad-spectrum antiviral drug candidate, NV-387, targeting MPox and acute respiratory infections. NV-387, which completed Phase 1 trials for safety, is expected to begin Phase 2 trials for MPox in late CY25 or early CY26, with potential biodefense funding. A second Phase 2 study for various respiratory viruses like flu, RSV, and coronaviruses is planned for India, potentially starting in winter 2026.
2025-10-15 16:37:07
NanoViricides, Inc. (NNVC) is advancing its broad-spectrum antiviral drug, NV-387, into Phase II clinical trials for both MPox and acute respiratory infections. An analyst report highlights the company's dual-track development strategy, leveraging its nanopolymer micelle technology to directly target and destroy virus particles. The trials are expected to begin with MPox in late 2025 or early 2026 in Congo, followed by an adaptive "basket-type" trial in India for various respiratory viruses like flu, RSV, and coronaviruses.
2025-10-15 15:54:39
NanoViricides, Inc. (NYSE American: NNVC) is pursuing a dual-track clinical strategy for its broad-spectrum antiviral drug candidate, NV-387, targeting MPox and acute respiratory infections. NV-387 has completed Phase 1 studies showing safety and tolerability, with Phase 2 trials expected to begin for MPox in late CY25 or early CY26, followed by adaptive "basket-type" trials for respiratory viruses in India. The company aims to address significant unmet medical needs and potential market opportunities for treatments against various viral diseases.
2025-10-15 14:34:06
NanoViricides (NNVC) is advancing its broad-spectrum antiviral drug, NV-387, into Phase II clinical trials with a dual-track strategy targeting MPox and acute respiratory infections. An analyst report highlights NV-387's safety and tolerability from a completed Phase 1 study and outlines planned trials in Congo for MPox and in India for respiratory viruses like flu, RSV, and coronaviruses. The company sees significant market opportunities in RSV and influenza, and has exclusive licenses to nanomedicine technology from TheraCour Pharma, Inc.
